A detailed history of Ims Capital Management transactions in Abb Vie Inc. stock. As of the latest transaction made, Ims Capital Management holds 17,640 shares of ABBV stock, worth $3.44 Million. This represents 1.39% of its overall portfolio holdings.

Number of Shares
17,640
Previous 17,713 0.41%
Holding current value
$3.44 Million
Previous $3.23 Million 6.2%
% of portfolio
1.39%
Previous 1.51%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 21, 2024

SELL
$154.79 - $180.76 $11,299 - $13,195
-73 Reduced 0.41%
17,640 $3.03 Million
Q1 2024

Jun 12, 2024

BUY
$159.82 - $182.1 $11,666 - $13,293
73 Added 0.41%
17,713 $3.23 Million
Q4 2023

Apr 01, 2024

SELL
$137.6 - $154.97 $3,715 - $4,184
-27 Reduced 0.15%
17,640 $2.73 Million
Q3 2023

Oct 10, 2023

BUY
$133.59 - $154.65 $1,870 - $2,165
14 Added 0.08%
17,667 $2.63 Million
Q2 2023

Sep 13, 2023

BUY
$132.51 - $164.9 $990,379 - $1.23 Million
7,474 Added 73.43%
17,653 $2.38 Million
Q1 2023

Sep 13, 2023

BUY
$144.61 - $166.54 $21,402 - $24,647
148 Added 1.48%
10,179 $1.62 Million
Q4 2022

Feb 22, 2023

SELL
$138.31 - $165.87 $217,976 - $261,411
-1,576 Reduced 13.58%
10,031 $1.62 Million
Q3 2022

Nov 17, 2022

BUY
$134.21 - $153.93 $231,914 - $265,991
1,728 Added 17.49%
11,607 $1.56 Million
Q2 2022

Jul 13, 2022

BUY
$137.62 - $174.96 $12,936 - $16,446
94 Added 0.96%
9,879 $1.51 Million
Q1 2022

Apr 08, 2022

BUY
$131.98 - $163.75 $1,451 - $1,801
11 Added 0.11%
9,785 $1.59 Million
Q4 2021

Jan 05, 2022

SELL
$107.43 - $135.93 $159,318 - $201,584
-1,483 Reduced 13.17%
9,774 $1.32 Million
Q3 2021

Oct 07, 2021

BUY
$106.4 - $120.78 $86,077 - $97,711
809 Added 7.74%
11,257 $1.21 Million
Q2 2021

Jul 07, 2021

BUY
$105.21 - $117.21 $252,714 - $281,538
2,402 Added 29.85%
10,448 $1.18 Million
Q1 2021

Apr 22, 2021

SELL
$102.3 - $112.62 $874,767 - $963,013
-8,551 Reduced 51.52%
8,046 $871,000
Q4 2020

Jan 12, 2021

BUY
$80.49 - $108.67 $146,250 - $197,453
1,817 Added 12.29%
16,597 $1.78 Million
Q3 2020

Nov 05, 2020

SELL
$85.91 - $100.83 $204,465 - $239,975
-2,380 Reduced 13.87%
14,780 $1.3 Million
Q2 2020

Jul 15, 2020

SELL
$73.37 - $98.18 $544,625 - $728,790
-7,423 Reduced 30.2%
17,160 $1.69 Million
Q1 2020

Apr 03, 2020

BUY
$64.5 - $97.79 $284,316 - $431,058
4,408 Added 21.85%
24,583 $1.87 Million
Q4 2019

Jan 15, 2020

SELL
$72.13 - $90.25 $52,582 - $65,792
-729 Reduced 3.49%
20,175 $1.79 Million
Q3 2019

Oct 09, 2019

BUY
$62.98 - $75.72 $332,471 - $399,725
5,279 Added 33.79%
20,904 $1.58 Million
Q2 2019

Aug 14, 2019

BUY
$65.7 - $83.98 $143,094 - $182,908
2,178 Added 16.2%
15,625 $1.14 Million
Q1 2019

May 21, 2019

BUY
$77.14 - $90.79 $1,851 - $2,178
24 Added 0.18%
13,447 $1.08 Million
Q4 2018

Feb 07, 2019

SELL
$77.85 - $96.01 $106,965 - $131,917
-1,374 Reduced 9.29%
13,423 $1.24 Million
Q3 2018

Nov 13, 2018

BUY
$88.91 - $98.84 $12,714 - $14,134
143 Added 0.98%
14,797 $0
Q2 2018

Jul 26, 2018

BUY
$89.78 - $106.23 $153,793 - $181,971
1,713 Added 13.24%
14,654 $1.36 Million
Q4 2017

Feb 14, 2018

SELL
$89.56 - $98.21 $140,877 - $154,484
-1,573 Reduced 10.84%
12,941 $1.25 Million
Q3 2017

Nov 14, 2017

BUY
$69.85 - $89.22 $1.01 Million - $1.29 Million
14,514
14,514 $1.29 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $344B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Ims Capital Management Portfolio

Follow Ims Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ims Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Ims Capital Management with notifications on news.